NASDAQ · Biotechnology

NervGen Pharma Corp. (NGEN) Stock

$1.73 -1.14% NASDAQ: NGEN Healthcare

Valuation

MetricValue
Price$1.73
Market Cap$142.19M
P/E Ratio-8.41
P/B Ratio108.37
P/S Ratio0.00
EPS (TTM)$-0.61
52-Week High$6.30
52-Week Low$1.58
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1466.67%
ROA-190.08%
ROCE-721.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio1.15

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-13.0M$-23.0M$-18.0M$-25.0M$-25.0M
Net Profit$-13.0M$-21.0M$-22.0M$-24.0M$-44.0M
EPS$-0.33$-0.39$-0.37$-0.36$-0.61
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$18.0M$24.0M$13.0M$19.0M$23.0M
Total Liabilities$1.0M$10.0M$15.0M$17.0M$20.0M
Cash$17.0M$22.0M$12.0M$17.0M$22.0M
Borrowings$0$0$0$0$0

Latest News

TD Cowen Initiates NervGen Pharma at Buy MT Newswires · Jun 11, 2026 NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study GlobeNewswire · May 26, 2026 Top Premarket Decliners MT Newswires · May 22, 2026 NervGen Pharma Prices $60 Million Share Offering MT Newswires · May 22, 2026 NervGen Announces Pricing of US$60.0 Million Public Offering of Securities GlobeNewswire · May 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-18.0M$-11.0M$-17.0M$-19.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$11.0M$4.0M$-10.0M$5.0M$5.0M
Free Cash Flow$-8.0M$-18.0M$-11.0M$-17.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.12
EV / EBITDA-15.42
FCF Yield-4.78%
Quick Ratio1.16
Interest Coverage0.00
Return 1Y-42.57%
Return 3Y32.82%
Return 5Y24.02%

Ownership

Insiders Held20.33%
Institutions Held2.07%
Institutions Float Held2.60%
Institutional HolderSharesReport Date
Pfg Investments, LLC 201,0002026-03-31
Marshall Wace LLP200,3592026-03-31
Bank of America Corporation200,6562026-03-31
Royal Bank of Canada171,9612026-03-31
Integrated Wealth Concepts LLC86,8152026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.68 -1.10% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About NervGen Pharma Corp.

NervGen Pharma Corp. is led by CEO Adam H. Rogers, employs 7 people, headquartered in CA, publicly traded since 2021.

NervGen Pharma Corp. (NGEN) stock trades at $1.73 with a market capitalization of $142.19M. The stock is valued at a price-to-earnings (P/E) ratio of -8.41, price-to-book of 108.37, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.58 and $6.30, and currently trades 72.5% below its 52-week high.

On profitability, NervGen Pharma Corp. generates a return on equity (ROE) of -1466.67%, return on capital employed of -721.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides